The effect of 1-furan-2-yl-3-pyridine-2-yl-propenone on pharmacokinetic parameters of warfarin
- 67 Downloads
1-Furan-2-yl-3-pyridine-2-yl-propenone (FPP-3) is an investigatory drug which has a dual inhibitory action on cyclooxygenase (COX) and 5-lipoxygenase (5-LOX). We examined its effect on the pharmacokinetics of warfarin. Three consecutive days of pretreatment with 17 mg/kg of FPP-3 had no significant effect on the pharmacokinetic parameters of warfarin when orally administered to rats. A higher dosage of FPP-3 however, did cause significant changes in the pharmacokinetic parameters of wafarin. The cytochrome P450 activity test demonstrated that the metabolism of R-warfarin was significantly inhibited by FPP-3 while there was little or no inhibition of the metabolism of S-warfarin, which is mainly responsible for its anticoagulant effect. Therefore, it appears that the alteration in the pharmacokinetic parameters of warfarin was due to the inhibitory effect of FPP-3 on the metabolism of R-warfarin. Although there was a significant increase in the plasma concentration, the area under the curve, half life of warfarin, and prothrombin time were not significantly changed. Based on these findings, the pharmacokinetic drug interaction between FPP-3 and warfarin mainly involves R-warfarin and, therefore, this interaction may not be of clinical significance in terms of warfarin-related toxicity.
Key words1-Furan-2-yl-3-pyridine-2-yl-propenone Warfarin Pharmacokinetics Cytochrome P450 Prothrombin time
- Burnier, M., The safety of rofecoxib. Expert Opin.Drug Saf., 4, 491–499 (2005).Google Scholar
- Lee, E., Ju, H., Moon, T, Lee, E., Jahng, Y, Lee, S., Son, J., Baek, S., and Chang, H., Inhibition of nitric oxide and tumor necrosis factor-alpha (TNF-alpha) production by propenone compound through blockade of nuclear factor (NF)-kappa B activation in cultured murine macrophages.Biol. Pharm. Bull., 27, 617–620 (2004).PubMedCrossRefGoogle Scholar
- Yacobi, A., Masson, E., Moros, D., Ganes, D., Lapointe, C., Abolfathi, Z., LeBel, M., Golander, Y, Doepner, D., Blumberg, T., Cohen, Y, and Levitt, B., Who needs individual bioequivalence studies for narrow therapeutic index drugs? A case for warfarin.J. Clin. Pharmacol., 40, 826–835 (2000).PubMedCrossRefGoogle Scholar